These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 25962998)

  • 1. A sample size planning approach that considers both statistical significance and clinical significance.
    Jia B; Lynn HS
    Trials; 2015 May; 16():213. PubMed ID: 25962998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methods for one-sided testing of the difference between proportions and sample size considerations related to non-inferiority clinical trials.
    Dann RS; Koch GG
    Pharm Stat; 2008; 7(2):130-41. PubMed ID: 17526060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calculation of tolerance limits and sample size determination for clinical trials with dichotomous outcomes.
    Zaslavsky BG
    J Biopharm Stat; 2007; 17(3):481-91. PubMed ID: 17479395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the statistical power for multiple tests: a case study.
    Yeo A; Qu Y
    Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiplicity-adjusted sample size requirements: a strategy to maintain statistical power with Bonferroni adjustments.
    Leon AC
    J Clin Psychiatry; 2004 Nov; 65(11):1511-4. PubMed ID: 15554764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size re-estimation for survival data in clinical trials with an adaptive design.
    Togo K; Iwasaki M
    Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimates, power and sample size calculations for two-sample ordinal outcomes under before-after study designs.
    Strickland PA; Lu SE
    Stat Med; 2003 Jun; 22(11):1807-18. PubMed ID: 12754716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence assessment for interchangeability based on two-sided tests.
    Dong X; Tsong Y
    J Biopharm Stat; 2014; 24(6):1312-31. PubMed ID: 25032976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothesis testing and effect size estimation in clinical trials.
    Borenstein M
    Ann Allergy Asthma Immunol; 1997 Jan; 78(1):5-11; quiz 12-6. PubMed ID: 9012613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weighted evidence approach of bridging study.
    Tsou HH; Tsong Y; Liu JT; Dong X; Wu Y
    J Biopharm Stat; 2012 Sep; 22(5):952-65. PubMed ID: 22946942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
    Kombrink K; Munk A; Friede T
    Stat Med; 2013 Aug; 32(18):3055-66. PubMed ID: 23508697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
    Zhang F; Miyaoka E; Huang F; Tanaka Y
    J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size calculations with multiplicity adjustment for longitudinal clinical trials with missing data.
    Lu K
    Stat Med; 2012 Jan; 31(1):19-28. PubMed ID: 22162151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T; Kieser M
    Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical midcourse sample size modification in clinical trials.
    Proschan MA; Liu Q; Hunsberger S
    Control Clin Trials; 2003 Feb; 24(1):4-15. PubMed ID: 12559638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian sample size determination for a clinical trial with correlated continuous and binary outcomes.
    Stamey JD; Natanegara F; Seaman JW
    J Biopharm Stat; 2013; 23(4):790-803. PubMed ID: 23786161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size re-estimation for adaptive sequential design in clinical trials.
    Gao P; Ware JH; Mehta C
    J Biopharm Stat; 2008; 18(6):1184-96. PubMed ID: 18991116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.